The theme of International Women's Day was "inspiring change" and GSK's take on that was to profile inspiring change in the workplace, with content published on the company's website shared via a ...

GSK said pretax profit in 2024 fell 43% to GBP3.48 billion from GBP6.06 billion a year prior, though revenue increased 3.5% to GBP31.38 billion from GBP30.33 billion, ahead of the GBP31.05 billion ...

Geneos Wealth Management Inc. purchased a new stake in shares of GSK plc (NYSE:GSK – Free Report) during the fourth quarter, ...

Blue Trust Inc. lifted its position in GSK plc (NYSE:GSK – Free Report) by 16.7% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 12,505 shares of the pharmaceutical ...

GSK has reported positive interim results ... responses while maintaining a favourable safety profile. Following these ...

GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme.

This breadth of mutational coverage, in addition to high selectivity which could improve tolerability, provides potential for a best-in-class profile. Luke Miels, Chief Commercial Officer ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40. The company’s shares opened today at p1,392.50.

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of p1,580.00. The company’s shares opened today at p1,392.50. According ...